AlphAIalphai — Financial news for AI agents
pharmaceutical-business-review.comAUG 46 min read$LNTH

Curium to buy Lantheus in all

Curium US will buy all outstanding shares of Nasdaq-listed Lantheus for $102.50 per share at closing, plus non-transferable CVRs worth up to $12.00 more if 2030 milestones are met, for up to $114.50 total. The offer is a 38% premium to Lantheus’ 60-day VWAP. Board approved unanimously; deal expected to close in H1 2027.

Original reporting
pharmaceutical-business-review.com
Published Aug 4, 2026, 1:15 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 4, 2026, 1:31 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
Curium to buy Lantheus in all — source image
Source · pharmaceutical-business-review.com
Decision brief

The 30-second read

$LNTHBullishHigh
01

Why it matters

The disclosed per-share price, CVR structure, premium levels, unanimous board approval, and expected closing timeline create a tradable M&A catalyst for both the target (LNTH) and acquirer (CRMD), with key risks centered on regulatory and shareholder approvals and financing/integration execution.

02

Market read

A take-private M&A deal with defined consideration and CVR upside is announced, setting up deal-spread trading and approval-risk positioning through 1H 2027.

03

What to watch

Financing is via debt and equity, but the article provides no leverage or dilution details; integration execution and CVR milestone achievability could materially affect realized value.

Relevance 9/10Novelty 9/10Timing: deal terms announced today, with closing expected in 1H 2027 subject to approvals

Background

Curium and Lantheus are radiopharmaceutical and radiodiagnostics players; the article frames the transaction as combining Curium’s theranostics capabilities with Lantheus’ US-based radiodiagnostics business.

Company-level read

Ticker impact

$LNTHBullishHigh confidence
Context

Curium will buy all outstanding Lantheus shares for $102.50 per share, with CVRs potentially adding up to $12 more per share.

Expected impact

Bullish bias for LNTH on deal confirmation odds, with volatility tied to regulatory and shareholder approval through 1H 2027.

Evidence & confidence

The article discloses specific consideration ($102.50 plus up to $12 CVRs), premium metrics, unanimous board approval, and expected closing window, which are direct inputs to deal-spread valuation.

Market effects

Sector

Signals consolidation in radiopharmaceuticals and theranostics, potentially increasing M&A expectations and competitive pressure for US radiodiagnostics franchises.

Regional

Strengthens Curium’s US diagnostic presence (F18-based prostate diagnostics) and neurology/echocardiography reach.

Global

Creates a combined platform operating across more than 70 countries, potentially affecting global supply and commercial coverage in nuclear medicine.

Counterpoint

What could challenge this read

Deal spreads can widen if regulatory scrutiny or shareholder opposition emerges, so the announced premium may not fully protect downside in the interim.

Key entities

  • acquirer
    Curium

    Nasdaq-listed Curium US will purchase all outstanding Lantheus shares under the agreement.

  • target
    Lantheus

    Nasdaq-listed radiopharmaceutical company being taken private; shareholders receive $102.50 per share plus CVRs up to $12.

  • executive
    Mary Anne Heino

    Lantheus executive chair and CEO endorsing the transaction.

  • executive
    Renaud Dehareng

    Curium CEO describing strategic fit and integration rationale.

Read at source← All news

Also covered by

1 outlet

Related articles

AUG 6
$LNTHMed

Lantheus (NASDAQ:LNTH) Reports Upbeat Q2 CY2026

Lantheus Holdings (NASDAQ: LNTH) reported Q2 CY2026 revenue of $388.2 million, up 2.7% year on year, ahead of Wall Street expectations. Non-GAAP adjusted EPS was $1.55, 18.9% above consensus. The article also cites adjusted operating margin of 31% and analyst expectations for revenue to decline 3.2% and full-year EPS to fall from $5.95 to $5.55.

financialcontent.com5 min
AUG 6
$LNTHHighAI 10/10

Lantheus Holdings, Inc. (LNTH): Results of Operations and Financial Condition

Lantheus Holdings, Inc. (LNTH) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 lnth-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Lantheus Reports Second Quarter 2026 Financial Results • Worldwide revenue of $388.2 million in the second quarter of 2026 • GAAP fully diluted earnings per share of $1.11, compared to $1.12 in the second quarter of 2025 • Ad

SEC EDGAR 8-K6 min
AUG 3
$LNTHMed

TD Cowen downgrades Lantheus stock to hold on Curium deal view

TD Cowen downgraded Lantheus Holdings (LNTH) to Hold from Buy and cut its price target to $102.50 from $110.00. Analyst Tara Bancroft said the Curium deal is fair and sees >50% odds of most contingent value milestones, but less optimism on the top PSMA PET tier. The stock trades near $102.03. Separately, the FDA issued a Complete Response Letter for LNTH-2501.

investing.com4 min
AUG 3
$LNTHHighAI 9/10

Lantheus Holdings To Be Acquired By Curium For Up To $8 Bln

Lantheus (LNTH) said it agreed to be acquired by Curium, backed by CapVest, for up to $8 billion. Curium US will buy all LNTH shares for $102.50 cash plus non-transferable Contingent Value Rights up to $12 per share tied to milestones through 2030. Total up to $114.50 per share, a 38% premium. Deal expected to close in 1H 2027.

rttnews.com4 min